China Covid-19 vaccine may be ready for public in November

Henrietta Brewer
September 15, 2020

On September 12, Pfizer and BioNTech have jointly issued a press release stating that both the companies were expecting a "conclusive readout" on the efficacy of their Coronavirus vaccine candidate and it would likely be published by the end of October.

It is hoped that by directly targeting the cells that line the airways - the point at which infection begins - the aerosolised vaccine may induce a more effective immune response, versus an injection.

Dr. Anthony Fauci, the top infectious disease expert on the US government's coronavirus task force, agreed on Wednesday that the temporary halting of the Phase-3 Oxford vaccine trial was "not uncommon".


As pharmaceutical companies in the USA and around the world work with government agencies to build a reliable timeline toward offering the world a viable vaccine, we seem to be in a hypothetical tug-o-war, with President Trump's administration pulling the date back to sometime this year, and other experts - some scientific, some private - arguing for more time. Bourla said the decision to increase the number of participants stems from its desire to expand to more vulnerable populations.

From the ramparts of Red Fort, he had said three vaccines were in different stages of testing, and the plan for production was ready.

The US has signed a $1.95 billion agreement with Pfizer and BioNTech for at least 100 million doses of its coronavirus vaccine after it is approved by the FDA, with room for acquisition of another 500 million doses. Plus, he added, he wanted to keep Pfizer out of politics, a tall task for a pharma company on any day, but especially during this pandemic.


Meanwhile, the United Kingdom trial of a leading coronavirus vaccine, which was abruptly halted last week because of safety concerns, restarted on Saturday after the university conducting the trial said an independent committee found that it was safe to do so. With the flu, we have a virus that's changing all of the time. "But with SARS-COVID-2, it seems to be a pretty constant", he said.

When this happened late last week, Poonawala tweeted, "a$3 s I'd mentioned earlier, we should not jump to conclusions until the trials are fully concluded".


Other reports by iNewsToday

FOLLOW OUR NEWSPAPER